Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. monthly Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.98 Insider Own0.30% Shs Outstand161.25M Perf Week2.44%
Market Cap11.30B Forward P/E- EPS next Y-2.03 Insider Trans-6.13% Shs Float160.98M Perf Month-16.69%
Income-310.20M PEG- EPS next Q0.67 Inst Own100.00% Short Float3.94% Perf Quarter-37.60%
Sales893.50M P/S12.65 EPS this Y28.10% Inst Trans7.46% Short Ratio3.74 Perf Half Y-49.07%
Book/sh14.25 P/B4.92 EPS next Y-222.20% ROA-9.20% Target Price132.72 Perf Year-26.85%
Cash/sh3.83 P/C18.28 EPS next 5Y25.00% ROE-14.40% 52W Range62.12 - 151.75 Perf YTD-33.10%
Dividend- P/FCF- EPS past 5Y37.13% ROI-4.70% 52W High-53.82% Beta1.05
Dividend %- Quick Ratio2.30 Sales past 5Y18.30% Gross Margin82.60% 52W Low12.81% ATR5.43
Employees1681 Current Ratio3.00 Sales Q/Q18.40% Oper. Margin-30.30% RSI (14)36.29 Volatility7.12% 7.57%
OptionableYes Debt/Eq0.29 EPS Q/Q- Profit Margin-34.70% Rel Volume1.27 Prev Close67.26
ShortableYes LT Debt/Eq0.29 EarningsFeb 25 AMC Payout- Avg Volume1.69M Price70.08
Recom2.00 SMA20-7.54% SMA50-21.98% SMA200-39.18% Volume2,156,207 Change4.19%
Jan-20-16Initiated Credit Suisse Outperform
Jan-19-16Reiterated Wedbush Neutral $125 → $117
Nov-25-15Reiterated Oppenheimer Perform $119 → $115
Nov-18-15Initiated Goldman Buy
Oct-05-15Reiterated Wedbush Neutral $131 → $137
Oct-02-15Initiated Raymond James Outperform $148
Sep-01-15Initiated Raymond James Outperform $148
Jul-08-15Reiterated RBC Capital Mkts Outperform $145 → $155
Jun-19-15Downgrade Robert W. Baird Outperform → Neutral $125 → $133
Jun-18-15Reiterated Sun Trust Rbsn Humphrey Buy $151 → $170
Jun-18-15Reiterated RBC Capital Mkts Outperform $125 → $145
Jun-18-15Reiterated Piper Jaffray Overweight $123 → $147
Jun-18-15Reiterated Jefferies Buy $135 → $150
Jun-18-15Reiterated Deutsche Bank Buy $140 → $156
Jun-18-15Reiterated Canaccord Genuity Buy $115 → $150
Jun-05-15Initiated Barclays Overweight $150
May-27-15Reiterated JP Morgan Overweight $125 → $140
May-01-15Reiterated JP Morgan Overweight $120 → $125
Mar-27-15Reiterated UBS Buy $112 → $136
Mar-27-15Reiterated Deutsche Bank Buy $90 → $140
Feb-11-16 06:05PM  [$$] Gilead Way Oversold As Investors Flee Biotech at Barrons.com
03:27PM  Blame these 11 stocks for Nasdaq nightmare at USA TODAY
Feb-08-16 11:46AM  BioMarin Pharmaceutical's Illness Could Be Cured -5.36%
Feb-07-16 02:40PM  Why Shares of Sarepta Therapeutics Inc. Collapsed in January at Motley Fool
Feb-04-16 02:29PM  Its Time to Buy This Biotech Gem
Feb-03-16 09:01AM  Headline Risk Is Poison for Pharma and Biotech
Feb-01-16 08:00AM  Pre-Market Pulse on Biotechnology Stocks -- ZIOPHARM Oncology, BioMarin Pharma, PTC Therapeutics, and Vertex Pharma Accesswire
Jan-28-16 08:52AM  BioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET at noodls -8.44%
08:30AM  BioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET GlobeNewswire
Jan-27-16 10:39AM  Will 2016 Be BioMarin Pharmaceutical's Best Year Yet? at Motley Fool -6.86%
Jan-26-16 06:45AM  Akashi suspends drug trial in latest setback for Duchenne community at bizjournals.com
12:06AM  Changes in BioMarins Valuation Multiples
Jan-25-16 08:10AM  Duchenne drug by Cambridge's Catabasis looks safe in early trial at bizjournals.com
Jan-22-16 02:41PM  Snowstorm Dashes Hopes for Sarepta Drug's Dystrophy Patients at Bloomberg
Jan-21-16 11:23AM  The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug
Jan-20-16 08:01PM  Muscular Dystrophy Drugs Face New FDA Questions at The Wall Street Journal
03:50PM  Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie
02:40PM  Four big problems with the FDAs analysis of Sareptas Duchenne drug data at bizjournals.com
02:31PM  Why BioMarin's Pipeline Could Be Worth $4 Billion-Plus
11:07AM  10 Biotech Buys from Credit Suisse at Barrons.com
06:12AM  Coverage initiated on Biomarin Pharm by Credit Suisse
Jan-19-16 01:47PM  What Are the Potential Drivers of BioMarin?
01:47PM  What Are Analysts Expectations for BioMarin?
12:20PM  Science, and not patients, will turn the tide for Sarepta's Duchenne drug at bizjournals.com
Jan-15-16 03:13PM  [$$] Setback for Sarepta Drug, But Approval Still Possible at Barrons.com
02:25PM  BioMarin's DMD Drug Kyndrisa Receives CRL from the FDA
12:53PM  Sarepta Plummets As FDA Slams Muscular Dystrophy Drug at Investor's Business Daily
12:14PM  Sarepta: 'Approval Unlikely,' Shares Tank at Barrons.com
11:32AM  Sarepta Therapeutics shares tank as hopes for new drug approval fade at MarketWatch
10:20AM  Here's Why Sarepta Therapeutics Is Getting Crushed Today at Motley Fool
10:05AM  Why Sarepta Therapeutics Is Cratering at 24/7 Wall St.
09:29AM  Sarepta Plunges on Harsh FDA Eteplirsen Review Ahead of Next Week's Advisory Panel Meeting at TheStreet
07:15AM  Packed house expected at the FDAs Duchenne drug hearing next week at bizjournals.com
05:00AM  Pharma Investors Look for Lessons After BioMarin FDA Defeat at Bloomberg
12:22AM  [$$] FDA Rejects New Drug Application for BioMarins Duchenne Treatment at The Wall Street Journal
Jan-14-16 05:52PM  Biotech name to watch
01:20PM  BioMarin's Orphan Wizardry Fails at Bloomberg
12:29PM  BioMarin Muscular Dystrophy Drug Rejected By FDA at Investor's Business Daily
12:03PM  [$$] FDA Rejects New Drug Application for BioMarin's Duchenne Treatment at The Wall Street Journal
11:36AM  FDA rejects BioMarin's muscle wasting drug; Sarepta drug in focus Reuters
08:50AM  BioMarin Fails to Win Approval for Drug to Treat Duchenne at Bloomberg
08:43AM  BioMarin's stock falls after FDA says it's not ready to approve NDA for MS drug at MarketWatch
08:37AM  FDA rejects BioMarin's muscle-wasting disorder drug Reuters
08:30AM  FDA Issues Complete Response Letter for KyndrisaTM for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping GlobeNewswire
Jan-13-16 04:39PM  Why BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc, and ImmunoGen, Inc. Got Clobbered Today at Motley Fool -9.66%
03:04PM  The FDA's Change of Heart Sends Sarepta Therapeutics' Shares Soaring in 2015 at Motley Fool
01:41PM  3 Biotechs With Major Catalysts Incoming at Motley Fool
11:40AM  Duchenne pioneer says FDA rejection of Sareptas drug would be a travesty at bizjournals.com
Jan-12-16 06:10PM  Drug pricing is all about balance: CEOs at CNBC
02:50PM  BioMarin Reveals Interim Data from Pompe Disease Study
02:47PM  Bristol-Myers CEO: Looking forward to 2016
01:13PM  BioMarin CEO on drug pricing, approval
Jan-11-16 02:01PM  Yes, this company has rare disease news, but there's much more to come at bizjournals.com
11:30AM  BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease at 34th Annual J.P. Morgan Annual Healthcare Conference GlobeNewswire
10:24AM  Day 1 of #JPM16: Liquid biopsies, rare diseases and off-the-record keynotes at bizjournals.com
Jan-08-16 11:58AM  Patient-funded biotech in $100 mln funding deal for DMD drug Reuters
Jan-07-16 04:02PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisi
Jan-06-16 08:14AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : January 6, 2016
Jan-05-16 11:45AM  Acceleron to raise $150M in stock offering for muscular dystrophy studies at bizjournals.com
11:36AM  Stick With Biotech in 2016? at Barrons.com
08:55AM  The Top 5 Large Cap Biotechnology Stocks for 2016 (AMGN, BIIB) at Investopedia
08:30AM  BioMarin to Present at 34th Annual J.P. Morgan Healthcare Conference in San Francisco GlobeNewswire
Jan-04-16 08:30AM  BioMarin Announces Addition of David Pyott, Former Allergan Chairman and CEO, to Companys Board of Directors GlobeNewswire
Jan-03-16 08:21AM  What Does 2016 Hold for Biotech Stocks? at Motley Fool
Jan-02-16 10:15AM  4 Top FDA Decisions Expected in Q1 at 24/7 Wall St.
Dec-31-15 05:04PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers
Dec-30-15 04:25PM  Sarepta's DMD Drug Eteplirsen to Face FDA Panel in January
07:00AM  Healthcare: Even After Uptick, Some Great Values Remain at Morningstar
Dec-28-15 02:24PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-26-15 12:30PM  Sell These 6 Biotech Stocks Now Before It's Too Late at TheStreet
Dec-24-15 09:30AM  The Zacks Analyst Blog Highlights: Actelion, Amgen, Gilead, AbbVie and BioMarin
Dec-23-15 02:48PM  Biotech Stock Roundup: KaloBios Removes CEO Shkreli, Actelion PAH Drug Approved
Dec-21-15 04:47PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers
04:20PM  BioMarin's (BMRN) Kyndrisa Review Period Extended by FDA
02:08PM  BioMarin Rises, FDA Has Yet to Complete Its Review of Kyndrisa
12:17PM  What Does Gilead Want to Do? at Barrons.com
09:25AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : December 21, 2015
Dec-18-15 04:44PM  BioMarin, Intercept Pharma Drugs Face FDA Delays at Investor's Business Daily
12:27PM  FDA delays BioMarin drug approval, gives investors hope Reuters
08:43AM  BioMarin says FDA to delay deciding on approval of DMD drug Reuters
08:30AM  BioMarin Announces That FDA Has Advised it Will Not Take Action on the Kyndrisa (drisapersen) New Drug Application by the PDUFA Date GlobeNewswire
Dec-17-15 03:18PM  3 Convertible Bonds That Belong in Your Portfolio at TheStreet
02:04PM  Three Biotech Stocks for 2016 at Barrons.com
Dec-15-15 05:35PM  Soaring North Bay biotech company grabs Peninsula space to woo workers at bizjournals.com +5.21%
Dec-14-15 01:07PM  BioMarins Share Price Falls on Negative Investor Sentiment
01:07PM  How Would Kyndrisa Treat Duchenne Muscular Dystrophy?
Dec-11-15 12:56PM  FDA Committee Raises Concerns about Kyndrisas Efficacy, Safety
12:56PM  FDA Sets December 27, 2015, as Kyndrisas PDUFA Date
Dec-08-15 01:16PM  BIOMARIN PHARMACEUTICAL INC Financials
08:29AM  Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas
Dec-05-15 08:03AM  Why a Failure By BioMarin Caused Sarepta's Shares to Spike 53% in November at Motley Fool
Dec-02-15 11:58AM  Why This May be the Best Opportunity in Biotech
10:20AM  4 Top Jefferies Biotech and Specialty Pharma Growth Stocks to Buy Now at 24/7 Wall St.
06:11AM  Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics at TheStreet
Dec-01-15 04:03PM  Top Stock Picks of Multi-Billion Dollar, Healthcare-Focused Fund Palo Alto Investors at Insider Monkey
01:14PM  CEO still bullish on drug for rare disease at CNBC
01:00PM  New Additions Highlight Billionaire Kyle Bass Top Stock Picks for Q4 at Insider Monkey
Nov-30-15 07:10PM  Is BioMarin Pharmaceutical Inc. (BMRN) A Good Stock To Buy? at Insider Monkey
01:42PM  Morgan Stanley is Wrong: This Biotech Could Explode Higher
11:40AM  Most popular BioFlash stories from November: Its all about the battle in Duchenne at bizjournals.com
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerNov 30Sale94.741,00094,74425,758Dec 02 06:58 PM
GREY MICHAEL GDirectorNov 16Option Exercise38.597,500289,42533,750Nov 18 04:49 PM
LAWLIS V BRYANDirectorNov 16Option Exercise17.337,500129,97519,350Nov 18 05:10 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 16Option Exercise39.0620,000781,20048,229Nov 18 04:03 PM
LAWLIS V BRYANDirectorNov 16Sale104.261,050109,46811,850Nov 18 05:10 PM
GREY MICHAEL GDirectorNov 16Sale104.277,500782,05426,250Nov 18 04:49 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerNov 16Sale104.3020,0002,085,91828,229Nov 18 04:03 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 02Sale117.56263,05735,605Nov 06 05:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 15Sale108.241,000108,24126,758Oct 19 01:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 14Sale131.431,000131,43227,758Sep 16 08:09 PM
HERON ELAINE JDirectorSep 08Option Exercise21.5115,000322,65035,625Sep 25 12:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 12Sale134.721,500202,08328,758Aug 13 10:40 AM
Ajer Jeffrey RobertSVP, Chief Commercial OfJul 20Option Exercise63.103,000189,30038,605Jul 22 03:21 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJul 20Sale150.003,000450,00035,605Jul 22 03:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 07Sale139.071,500208,60030,258Jul 09 05:06 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 05Sale122.301,649201,66928,229Jun 08 06:09 PM
FUCHS HENRY JEVP, Chief Medical OfficerJun 05Sale122.321,864228,00172,846Jun 08 06:06 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 04Sale122.351,362166,64635,605Jun 08 05:43 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 01Sale124.163,945489,81131,679Jun 03 08:27 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 01Sale123.7637746,65738,455Jun 03 08:23 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 29Sale126.151,578199,06535,624Jun 03 08:27 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 26Sale126.551,625205,64739,245May 26 07:52 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 18Sale124.781,864232,58476,746May 19 07:21 PM
Davis George EricSVP, General CounselMay 18Sale125.262,558320,41569,226May 19 07:18 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 18Sale130.0034,0784,430,14041,507May 28 05:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale121.371,434174,03880,646May 14 06:54 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 11Sale121.642,869348,98883,646May 12 07:27 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 06Option Exercise33.9333,6311,141,21576,664May 08 05:49 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 06Sale119.1434,0194,053,04242,645May 08 05:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Option Exercise6.4623,218149,98856,476May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale114.9823,2182,669,51733,258May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale114.983,505402,992248,654May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Option Exercise6.4622,546145,64755,804Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Sale120.5322,5462,717,54633,258Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Sale120.533,506422,590251,251Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 20Sale126.401,000126,39633,258Mar 24 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 17Sale124.871,000124,86634,258Mar 18 08:02 PM
FUCHS HENRY JEVP, Chief Medical OfficerMar 16Option Exercise21.5140,000860,400129,950Mar 18 07:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale123.481,000123,47735,258Mar 18 08:02 PM
FUCHS HENRY JEVP, Chief Medical OfficerMar 16Sale123.5741,3155,105,16688,635Mar 18 07:50 PM
Davis George EricSVP, General CounselMar 13Option Exercise37.0815,000556,23988,846Mar 17 06:03 PM
Davis George EricSVP, General CounselMar 13Sale120.8715,0001,813,00273,846Mar 17 06:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Sale114.892,021232,20136,258Mar 11 06:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise12.9915,000194,85057,279Mar 11 06:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale112.1319,0002,130,38338,279Mar 11 06:32 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Option Exercise17.1114,051240,364123,751Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Option Exercise12.9910,000129,90052,279Mar 05 08:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Sale113.7010,0001,137,01642,279Mar 05 08:20 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Sale116.3714,0511,635,091109,700Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Option Exercise9.865004,93043,695Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Sale107.7191698,66042,279Mar 04 07:39 PM
LAPALME PIERREDirectorMar 03Option Exercise14.2420,000284,80050,150Mar 05 05:34 PM
Mueller BrianVP, Corporate ControllerMar 03Option Exercise28.237,000197,61015,800Mar 05 05:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 03Sale107.425,000537,097215,157Mar 04 07:39 PM
Mueller BrianVP, Corporate ControllerMar 03Sale109.467,000766,2108,800Mar 05 05:31 PM
LAPALME PIERREDirectorMar 03Sale106.5720,0002,131,40030,150Mar 05 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Option Exercise12.993,00038,97046,195Mar 04 07:39 PM
Davis George EricSVP, General CounselMar 02Option Exercise26.4923,000609,27087,246Mar 04 07:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Option Exercise39.0615,500605,43084,176Mar 04 07:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Sale107.0015,5001,658,50068,676Mar 04 07:48 PM
Davis George EricSVP, General CounselMar 02Sale108.3123,0002,491,02764,246Mar 04 07:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale107.963,000323,89343,195Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale108.445,000542,195220,157Mar 04 07:39 PM